Enhancement of the immunogenicity of DNA replicon vaccine ofClostridium botulinumneurotoxin serotype A byGM-CSFgene adjuvant (Q83338735)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21284488 AND SRC:MED&resulttype=core&format=json

21 January 2020

title

Enhancement of the immunogenicity of DNA replicon vaccine of Clostridium botulinum neurotoxin serotype A by GM-CSF gene adjuvant (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21284488 AND SRC:MED&resulttype=core&format=json

21 January 2020

Enhancement of the immunogenicity of DNA replicon vaccine ofClostridium botulinumneurotoxin serotype A byGM-CSFgene adjuvant (English)

1 reference

https://api.crossref.org/works/10.3109/08923971003782327

23 November 2024

1 reference

Clostridium botulinum

object named as

Clostridium botulinum

1 reference

Na Li

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21284488 AND SRC:MED&resulttype=core&format=json

21 January 2020

Yun-Zhou Yu

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21284488 AND SRC:MED&resulttype=core&format=json

21 January 2020

Wei-Yuan Yu

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21284488 AND SRC:MED&resulttype=core&format=json

21 January 2020

Zhi-Wei Sun

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21284488 AND SRC:MED&resulttype=core&format=json

21 January 2020

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21284488

23 November 2024

publication date

1 March 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21284488 AND SRC:MED&resulttype=core&format=json

21 January 2020

March 2011

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21284488

full work available at URL

23 November 2024

http://www.tandfonline.com/doi/pdf/10.3109/08923971003782327

1 reference

https://api.crossref.org/works/10.3109/08923971003782327

Immunopharmacology and Immunotoxicology

23 November 2024

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21284488 AND SRC:MED&resulttype=core&format=json

21 January 2020

volume

33

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21284488 AND SRC:MED&resulttype=core&format=json

21 January 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21284488 AND SRC:MED&resulttype=core&format=json

21 January 2020

page(s)

211-219

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21284488 AND SRC:MED&resulttype=core&format=json

Neurotoxins affecting neuroexocytosis

21 January 2020

cites work

1

1 reference

https://api.crossref.org/works/10.3109/08923971003782327

Botulinum and tetanus neurotoxins: structure, function and therapeutic utility

23 November 2024

2

1 reference

https://api.crossref.org/works/10.3109/08923971003782327

Development of vaccines for prevention of botulism

23 November 2024

3

1 reference

https://api.crossref.org/works/10.3109/08923971003782327

Production of vaccines against leading biowarfare toxins can utilize DNA scientific technology

23 November 2024

4

1 reference

https://api.crossref.org/works/10.3109/08923971003782327

Botulinum neurotoxin vaccines: past, present, and future

23 November 2024

5

1 reference

https://api.crossref.org/works/10.3109/08923971003782327

Protective vaccination with a recombinant fragment of Clostridium botulinum neurotoxin serotype A expressed from a synthetic gene in Escherichia coli

23 November 2024

6

1 reference

https://api.crossref.org/works/10.3109/08923971003782327

Development of recombinant vaccines for botulinum neurotoxin

23 November 2024

7

1 reference

https://api.crossref.org/works/10.3109/08923971003782327

Cloning, expression and evaluation of a recombinant sub-unit vaccine against Clostridium botulinum type F toxin

23 November 2024

8

1 reference

https://api.crossref.org/works/10.3109/08923971003782327

Interaction between the two subdomains of the C-terminal part of the botulinum neurotoxin A is essential for the generation of protective antibodies.

23 November 2024

9

1 reference

https://api.crossref.org/works/10.3109/08923971003782327

Characterization of the antibody response to the receptor binding domain of botulinum neurotoxin serotypes A and E.

23 November 2024

10

1 reference

https://api.crossref.org/works/10.3109/08923971003782327

Trivalent vaccine against botulinum toxin serotypes A, B, and E that can be administered by the mucosal route

23 November 2024

11

1 reference

https://api.crossref.org/works/10.3109/08923971003782327

Subunit vaccine against the seven serotypes of botulism

23 November 2024

12

1 reference

https://api.crossref.org/works/10.3109/08923971003782327

The recombinant Hc subunit of Clostridium botulinum neurotoxin serotype A is an effective botulism vaccine candidate

23 November 2024

13

1 reference

https://api.crossref.org/works/10.3109/08923971003782327

Protection with a recombinant Hc of Clostridium Botulinum neurotoxin serotype A from Escherichia coli as an effective subunit vaccine

23 November 2024

14

1 reference

https://api.crossref.org/works/10.3109/08923971003782327

Evaluation of a recombinant Hc of Clostridium botulinum neurotoxin serotype F as an effective subunit vaccine

23 November 2024

15

1 reference

https://api.crossref.org/works/10.3109/08923971003782327

Vaccination of mice with DNA encoding a large fragment of botulinum neurotoxin serotype A

23 November 2024

16

1 reference

https://api.crossref.org/works/10.3109/08923971003782327

DNA vaccination using the fragment C of botulinum neurotoxin type A provided protective immunity in mice

23 November 2024

17

1 reference

https://api.crossref.org/works/10.3109/08923971003782327

DNA vaccination protects against botulinum neurotoxin type F

23 November 2024

18

1 reference

https://api.crossref.org/works/10.3109/08923971003782327

Efficacy of DNA vaccines expressing the type F botulinum toxin Hc fragment using different promoters

23 November 2024

19

1 reference

https://api.crossref.org/works/10.3109/08923971003782327

Candidate vaccine against botulinum neurotoxin serotype A derived from a Venezuelan equine encephalitis virus vector system

23 November 2024

20

1 reference

https://api.crossref.org/works/10.3109/08923971003782327

Multiagent vaccines vectored by Venezuelan equine encephalitis virus replicon elicits immune responses to Marburg virus and protection against anthrax and botulinum neurotoxin in mice.

23 November 2024

21

1 reference

https://api.crossref.org/works/10.3109/08923971003782327

Enhanced immune responses using plasmid DNA replicon vaccine encoding the Hc domain of Clostridium botulinum neurotoxin serotype A

23 November 2024

22

1 reference

https://api.crossref.org/works/10.3109/08923971003782327

Improved immunogenicity and protective efficacy of a replicon DNA vaccine encoding the Hc domain of botulinum neurotoxin serotype A by electric pulses and protein boosting.

23 November 2024

23

1 reference

https://api.crossref.org/works/10.3109/08923971003782327

Individual and bivalent vaccines against botulinum neurotoxin serotypes A and B using DNA-based Semliki Forest virus vectors

23 November 2024

24

1 reference

https://api.crossref.org/works/10.3109/08923971003782327

Enhanced potency of plasmid DNA microparticle human immunodeficiency virus vaccines in rhesus macaques by using a priming-boosting regimen with recombinant proteins

23 November 2024

25

1 reference

https://api.crossref.org/works/10.3109/08923971003782327

Codon optimization of the tat antigen of human immunodeficiency virus type 1 generates strong immune responses in mice following genetic immunization

23 November 2024

26

1 reference

https://api.crossref.org/works/10.3109/08923971003782327

Co-administration of a CpG adjuvant (VaxImmune, CPG 7909) with CETP vaccines increased immunogenicity in rabbits and mice

23 November 2024

27

1 reference

https://api.crossref.org/works/10.3109/08923971003782327

Coimmunization with an optimized IL-15 plasmid results in enhanced function and longevity of CD8 T cells that are partially independent of CD4 T cell help

23 November 2024

28

1 reference

https://api.crossref.org/works/10.3109/08923971003782327

Effect on antibody and T-cell responses of mixing five GMP-produced DNA plasmids and administration with plasmid expressing GM-CSF.

23 November 2024

29

1 reference

https://api.crossref.org/works/10.3109/08923971003782327

Recruitment and expansion of dendritic cells in vivo potentiate the immunogenicity of plasmid DNA vaccines.

23 November 2024

30

1 reference

https://api.crossref.org/works/10.3109/08923971003782327

The combination of GM-CSF and IL-2 as local adjuvant shows synergy in enhancing peptide vaccines and provides long term tumor protection

23 November 2024

31

1 reference

https://api.crossref.org/works/10.3109/08923971003782327

Cytokine GM-CSF genetic adjuvant facilitates prophylactic DNA vaccine against pseudorabies virus through enhanced immune responses.

23 November 2024

32

1 reference

https://api.crossref.org/works/10.3109/08923971003782327

Th2-dominated antitumor immunity induced by DNA immunization with the genes coding for a basal core peptide PDTRP and GM-CSF.

23 November 2024

33

1 reference

https://api.crossref.org/works/10.3109/08923971003782327

Phase I/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanoma.

23 November 2024

34

1 reference

https://api.crossref.org/works/10.3109/08923971003782327

Comparative studies of Avipox-GM-CSF versus recombinant GM-CSF protein as immune adjuvants with different vaccine platforms

23 November 2024

35

1 reference

https://api.crossref.org/works/10.3109/08923971003782327

Coexpression of GM-CSF and antigen in DNA prime-adenoviral vector boost immunization enhances polyfunctional CD8 T cell responses, whereas expression of GM-CSF antigen fusion protein induces autoimmunity

23 November 2024

36

1 reference

https://api.crossref.org/works/10.3109/08923971003782327

Co-expression of granulocyte-macrophage colony-stimulating factor with antigen enhances humoral and tumor immunity after DNA vaccination

23 November 2024

37

1 reference

https://api.crossref.org/works/10.3109/08923971003782327

Intramuscular immunization with a monogenic plasmid DNA tuberculosis vaccine: Enhanced immunogenicity by electroporation and co-expression of GM-CSF transgene

23 November 2024

38

1 reference

https://api.crossref.org/works/10.3109/08923971003782327

Codelivery of a DNA vaccine and a protein vaccine with aluminum phosphate stimulates a potent and multivalent immune response.

23 November 2024

39

1 reference

https://api.crossref.org/works/10.3109/08923971003782327

Enhancement of DNA vaccine potency using conventional aluminum adjuvants

23 November 2024

40

1 reference

https://api.crossref.org/works/10.3109/08923971003782327

Enhanced type I immune response to a hepatitis B DNA vaccine by formulation with calcium- or aluminum phosphate

23 November 2024

41

1 reference

https://api.crossref.org/works/10.3109/08923971003782327

23 November 2024

Identifiers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21284488 AND SRC:MED&resulttype=core&format=json

21 January 2020

1 reference